Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:cyclophosphamide
|
| gptkbp:activities |
gptkb:weapon
|
| gptkbp:appointed_by |
oral tablet
intravenous injection |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Cytoxan
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:contraindication |
pregnancy
active infections |
| gptkbp:discovered_by |
1950s
|
| gptkbp:duration |
varies by condition
|
| gptkbp:education |
regular follow-up appointments
avoid live vaccines report signs of infection monitor for bleeding hydration recommended |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral solution
lyophilized powder solution for injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Cytoxan
|
| gptkbp:indication |
gptkb:healthcare_organization
gptkb:psychologist nephrotic syndrome |
| gptkbp:ingredients |
gptkb:cyclophosphamide
C7 H15 Cl2 N2 O2 P |
| gptkbp:interacts_with |
gptkb:warfarin
live vaccines |
| gptkbp:is_atype_of |
L01 A A01
|
| gptkbp:is_monitored_by |
blood tests
|
| gptkbp:is_used_for |
treating cancer
treating autoimmune diseases |
| gptkbp:manager |
oral
intravenous |
| gptkbp:marketed_as |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
immunosuppressive effects
peak plasma concentration 1-2 hours after administration bioavailability 100% (IV) cytotoxic effects half-life 7 hours |
| gptkbp:shelf_life |
3 years
|
| gptkbp:side_effect |
nausea
vomiting hair loss cardiotoxicity low blood cell counts secondary malignancies bladder toxicity |
| gptkbp:storage |
room temperature
|
| gptkbp:type_of |
6055-19-2
|